Can a pharmaceutical company sell or license its data to AI companies, and what is it worth?
Possibly. No buyer publishes a pharmaceutical ceiling, so we state none; biotech labs list $750K–$1M. FDA rules keep unapproved applications confidential, and patient-level trial data needs HIPAA-grade de-identification before any copy leaves.
What could your company's records earn? Get a range in 30 seconds. Free, no obligation.
What is pharmaceutical data worth to AI buyers?
No buyer publishes a pharmaceutical ceiling or staff band, so this page gives none. The nearest published category is biotech and life sciences labs with 10 to 1,000 staff, at $750K–$1M for lab notebooks and experiment records. Digital health companies with 10 to 500 staff list $750K–$1M for consented visit recordings, transcripts and notes (buyer listings, read 20 Nov 2026). One general buyer program names "lab protocols" and "healthcare procedures" among wanted records and states a range of $100K to $4M+ across industries (buyer program page, read 21 Nov 2026). See all published ceilings.
Which pharmaceutical records do buyers want?
| Record | What it shows | Main limit |
|---|---|---|
| Lab protocols | Step-by-step methods | Licensed methods |
| Research documentation | Hypotheses, results, reviews | Unpublished discoveries |
| Experiment records | Conditions and outcomes, including failures | Partner ownership |
| Trial operations records | How studies were run | Patient-level detail |
| Manufacturing batch records | Process control | Quality rules and trade secrets |
Our research also names research documentation and protocols as the likely pharma fit. That list is a judgment, not a published listing.
What does FDA confidentiality mean for sharing?
FDA rules protect what you file with the agency, not what you hold. Under 21 CFR 312.130, FDA does not disclose that an investigational new drug application exists unless it has been publicly disclosed or acknowledged. Under 21 CFR 314.430, if an unapproved drug application's existence has not been publicly disclosed or acknowledged, no data or information in it is available for public disclosure (eCFR, read 21 Nov 2026).
Two lessons follow. First, the agency does not stop you from sharing your own copy, but you are choosing to open what FDA keeps closed. Second, once you license records, a buyer may learn of unfiled programs. A confidentiality term and a short scope matter. See the contract clauses to check.
What does HIPAA add for patient data?
HHS guidance describes two ways to de-identify protected health information under the HIPAA Privacy Rule: Expert Determination and Safe Harbor (HHS Office for Civil Rights, de-identification guidance, read 21 Nov 2026). Patient-level trial data must meet one of them, or have patient authorization, before sharing. Consent forms for trials may also restrict secondary use, so read yours. Our de-identification guide explains the basics.
What systems hold pharma records?
Electronic lab notebooks, laboratory information systems, clinical trial management systems, document control systems and quality systems. Buyers pay more for records linked from protocol to result.
How do I get a range?
Use the calculator with your staff and years of records. Pick the closest industry, biotech, and treat the result as a rough guide.
What does a sample record look like?
Three of the five record types this page lists: lab protocols, experiment records and research documentation, each linked from protocol to result.
- Method
- Cell assay, 14 steps, version 3.2
- Revisions
- 5 revisions over 18 months
- Linked to
- Experiment records that used this protocol
- Outcome
- Replaced version 3.1 after a signal drift problem
- Personal details
- Scientist names replaced with roles
- Conditions
- Dose series of 8 levels, 48 hour incubation
- Result
- Target effect at level 5, failed at level 8
- Failure noted
- Contaminated plate, rerun in 4 days
- Linked to
- Protocol version and research summary
- Partner ownership
- Cleared, no joint work in scope
- Personal details
- Analyst names removed
- Hypothesis
- Compound class improves response in model A
- Review
- 2 internal review rounds, 11 comments
- Decision
- Dropped after round 2, no filing made
- Linked to
- Experiment records supporting the decision
- Unfiled program check
- Excluded: contains unfiled program detail
- Personal details
- Reviewer names replaced with roles
Illustrative samples: invented values, real record types.
What has company data sold for?
We record 40 public data sales, each with its price, date and source. Search all 40 recorded data sales.
Questions
Can I license completed clinical trial data?
Only after de-identification under HIPAA and a check of the consent forms and trial agreements.
Does FDA confidentiality stop me?
It limits what FDA discloses. Your contracts and patient privacy rules limit what you share.
Why use biotech as the nearest price?
It is the closest published category. It is not a pharmaceutical figure.
Sources
- Buyer listings and program page, read 20 and 21 Nov 2026 (buyers not named by policy).
- 21 CFR 312.130, eCFR: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-D/section-312.130
- 21 CFR 314.430, eCFR: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-E/section-314.430
- HHS Office for Civil Rights, Guidance on De-identification of Protected Health Information: https://www.hhs.gov/hipaa/for-professionals/special-topics/de-identification/index.html